Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 6/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919408 | 0.96 | AKR1B1 (0.55) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 | |
| SCHEMBL920598 | 0.84 | ALDH1A1 (0.50) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 | |
| SCHEMBL11766486 | 0.83 | CALM1 (0.44) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 | |
| SCHEMBL224550 | 0.83 | TNKS2 (0.56) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 | |
| SCHEMBL23343786 | 0.82 | CYP4F2 (0.46) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 | |
| SCHEMBL31337521 | 0.82 | CALM1 (0.43) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 | |
| SCHEMBL9491787 | 0.81 | CYP19A1 (0.68) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 | |
| SCHEMBL23266717 | 0.81 | PTGS2 (0.58) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 | |
| SCHEMBL1050377 | 0.79 | PTGS2 (0.56) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 | |
| SCHEMBL5275704 | 0.79 | PTGS2 (0.56) | AKR1B1CYP19A1ALDH1A1CALM1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289109-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-31 | — | — | US | disclosed |
| US-8501809-B2 | Inhibitors of α4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20110077299-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2011-03-31 | — | — | US | disclosed |
| US-7872151-B2 | asthma, allergic conditions such as rhinitis, inflammatory bowel disease such as ulcerative colitis and Crohn's disease, rheumatoid arthritis, atopic dermatitis, multiple sclerosis; condensing N-(2,6-Difluorobenzoyl)-4-(2,6-dimethoxy-4-formal methylphenyl)-L-phenylalanine ethyl ester with ethanol | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100113820-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2010-05-06 | — | — | US | disclosed |
| US-7671090-B2 | Administering N-(2,6-Dichlorobenzoyl)-4-(2,6-dimethoxy-4-methoxymethylphenyl)-L-phenylalanine ethyl ester for therapy of asthma, inflammatory bowel disease, rheumatoid arthritis and atopic dermatitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20090111879-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | KAWAGUCHI TAKAYUKI | 2009-04-30 | — | — | US | disclosed |
| US-7456217-B2 | Inhibitors of alpha4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-11-25 | — | — | US | disclosed |
| EP-1049662-B1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-7026501-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20050282900-A1 | Inhibitors of alpha4 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1315694-B1 | INHIBITORS OF ALPHA 4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-20030176498-A1 | Inhibitors of alpha4mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1315694-A2 | INHIBITORS OF ALPHA 4 MEDIATED CELL ADHESION | Tanabe Seiyaku Co., Ltd. (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| WO-2002018320-A2 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282900-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | AKR1B1 869/4885CYP19A1 3891/4885ALDH1A1 372/4885 |
| US-20130289109-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | AKR1B1 869/4885CYP19A1 3891/4885ALDH1A1 372/4885 |
| US-20110077299-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | AKR1B1 869/4885CYP19A1 3891/4885ALDH1A1 372/4885 |
| US-20100113820-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | AKR1B1 869/4885CYP19A1 3891/4885ALDH1A1 372/4885 |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | AKR1B1 1432/4885CYP19A1 4724/4885ALDH1A1 312/4885 |
| US-20030176498-A1 | Inhibitors of alpha4mediated cell adhesion | ITGB4, VCAM1, EPCAM | AKR1B1 1573/4885CYP19A1 3949/4885ALDH1A1 158/4885 |
| US-20090111879-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | ITGB4, ITGA4, VCAM1 | AKR1B1 869/4885CYP19A1 3891/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.